The regulatory sweep found nothing new in the last 24 hours: no approvals, no safety communications and no guideline releases relevant to diabetes care.
The most recent items in the regulatory feeds are routine supplemental approvals from 11 August covering fixed-dose combination products already on the market — linagliptin and sitagliptin with metformin, and empagliflozin-based combinations, in both immediate and extended-release forms — plus a 6 August supplement for sotagliflozin. These are label and manufacturing supplements to existing applications, not new indications, and nothing in them changes prescribing.
On the guidance side, the most recent document worth knowing is the joint consensus statement from the European Association for the Study of Obesity and its dietetic and patient-organisation partners on the nutritional, functional and psychological aspects of incretin-based therapy, published in July. It sets out protein targets during rapid weight loss, progressive resistance exercise to protect fat-free mass, psychological screening, and shared decision-making around pausing or stopping treatment. It reads as a practical companion to the weight-regain data above, and no professional society has issued anything superseding it since.
- Nothing today requires a change to any prescription
- The August FDA items are supplements to existing combination products — no new indications
- The July incretin consensus statement remains the most current guidance on nutrition and monitoring during GLP-1 treatment
- Its core practical asks: adequate protein, resistance exercise, and psychological screening during rapid weight loss
- Check society sites directly for Indian guidance, which is not covered by these automated feeds
The statistics, in plain English
This section carries no trial statistics because there is nothing new to report. A consensus statement of this kind is expert opinion built on synthesised evidence, which sits below randomised trials in reliability but is the appropriate source where trials do not exist — nobody has randomised patients on incretin therapy to different protein targets, and probably nobody will.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free